ARCHIVES

In Brief: Norman Sharpless Named Director of UNC Lineberger

This article is from The Cancer Letter archive.

Vol. 39 No. 33 | September 6, 2013

Download PDF Visit The Full Archive

Related Articles

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

Wynder’s Low Fat Adjuvant Breast Cancer Study Finally Funded

October 21, 1988

Survivors With Gene Variant At More Risk For Heart Disease

June 25, 2010

Cancer Patients Satisfied With Experience In Clinical Trials, Survey Of 2,000 Finds

July 28, 2006

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

April 29, 1988

Evidence Links Anemia Drugs With Leukemic Transformation

December 28, 2007